Search

everythinglearnresearchcommunity

for

Search:↓

New testosterone analogs show promise for male contraception with better activity and potentially fewer side effects.

A woman's severe hormone imbalance after menopause led to finding a rare ovarian tumor, treated by surgery.

A woman with PCOS successfully overcame secondary infertility and became pregnant with triplets after treatment.

A certain gene variation is linked to a higher risk of polycystic ovarian syndrome in South Indian women.

Women over forty can maintain skin and hair health with lifestyle and dietary changes.

The guidelines recommend informed consent for gender-affirming treatments and stress the importance of personalized, culturally sensitive care for transgender individuals.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

Male hormones may play a role in the development of heart disease, and more research is needed to understand their effects.

The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.

Keratins help protect cells, aid in cancer diagnosis, and influence cancer behavior and treatment.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Women with the NIH type of PCOS have more obesity and higher risk of diabetes and heart disease than those with other types of PCOS.

PCOS is common among Chinese women of reproductive age and linked to serious metabolic and reproductive issues, especially in obese women.

The document likely offers guidance on treating a woman's excessive hair growth, considering her symptoms and obesity.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

The report recommends personalized treatment for women's sexual dysfunctions and more research on effective therapies.

Metformin helps manage polycystic ovary syndrome by improving insulin resistance and ovulation, but more research is needed on its full effects.

The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.

Lower doses of treatments for hirsutism and acne in PCOS are effective and cause fewer side effects.

Hormone treatments for transgender individuals generally improve mental health and physical transition, with some health risks that require medical supervision.

Testosterone therapy in transgender men has both desired effects like increased muscle mass and potential health risks such as higher cardiovascular risk.

Estrogens significantly influence hair growth by interacting with receptors in hair follicles and may help regulate the hair growth cycle.

Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.

People with alopecia areata often have other health issues like skin diseases, metabolic syndrome, stomach infections, lupus, anemia, thyroid problems, mental health issues, vitamin D deficiency, and hearing and eye problems.

Prolactin affects hair growth and skin conditions, and could be a target for new skin disease treatments.

Hormonal treatments, including birth control and antiandrogens, can effectively treat acne in women.

Certain genetic variations in the AR and ERβ genes can affect androgen levels in women.

Cholesterol sulfate buildup due to a genetic mutation disrupts the skin barrier, leading to the scaling skin seen in X-linked ichthyosis.

Gynecologists should provide comprehensive care for transgender patients, including mental health evaluation, hormone therapy, and surgical options, while monitoring for side effects and ensuring patient safety.

The conclusion is that managing androgen excess requires long-term treatment, including hormonal contraceptives and androgen blockers, with follow-up after six months.